CoChat

Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Screening for type 2 diabetes mellitus could lead to earlier identification and treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IGT), potentially resulting in improved outcomes. PURPOSE: To update the 2008 U.S. Preventive Services Task Force review on diabetes screening in adults. DATA SOURCES: Cochrane databases and MEDLINE (2007 through October 2014) and relevant studies from previous Task Force reviews. STUDY SELECTION: Randomized, controlled trials; controlled, observational studies; and systematic reviews. DATA EXTRACTION: Data were abstracted by 1 investigator and checked by a second; 2 investigators independently assessed study quality. DATA SYNTHESIS: In 2 trials, screening for diabetes was associated with no 10-year mortality benefit versus no screening (hazard ratio, 1.06 [95% CI, 0.90 to 1.25]). Sixteen trials consistently found that treatment of IFG or IGT was associated with delayed progression to diabetes. Most trials of treatment of IFG or IGT found no effects on all-cause or cardiovascular mortality, although lifestyle modification was associated with decreased risk for both outcomes after 23 years in 1 trial. For screen-detected diabetes, 1 trial found no effect of an intensive multifactorial intervention on risk for all-cause or cardiovascular mortality versus standard control. In diabetes that was not specifically screen-detected, 9 systematic reviews found that intensive glucose control did not reduce risk for all-cause or cardiovascular mortality and results for intensive blood pressure control were inconsistent. LIMITATION: The review was restricted to English-language articles, and few studies were conducted in screen-detected populations. CONCLUSION: Screening for diabetes did not improve mortality rates after 10 years of follow-up. More evidence is needed to determine the effectiveness of treatments for screen-detected diabetes. Treatment of IFG or IGT was associated with delayed progression to diabetes. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Overview

Integrity signals

Registry

Crossref · 10.7326/m14-2221

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

1 retracted

Show all 89 references

Research works printed but not linked: 4

  1. Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, 61, 918
  2. American Diabetes Association, 2015, Diabetes Care, 38, S1
  3. Van den Donk M, 2013, Diabetologia
  4. Wu H, 2010, Chin Med J (Engl), 123, 2908

Cited by

See all 134

Metadata

Authors
Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R.
Affiliations
Oregon Health & Science University (US)
Venue
Annals of Internal Medicine
Published
2015-06-02
Volume
162
Issue
11
Pages
765-776
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2086557545
Cited by
134
References
89
Citations by year
2026: 3 · 2025: 2 · 2024: 8 · 2023: 13 · 2022: 7 · 2021: 12 · 2020: 24 · 2019: 3 · 2018: 19 · 2017: 12 · 2016: 23 · 2015: 8
FWCI
2.98
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Public Health Service (HHSA 290-2007-10057-I)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, diabetes screening, impaired fasting glucose, impaired glucose tolerance, screen-detected diabetes, progression to diabetes, lifestyle modification, tight glycemic control, intensive blood pressure control, cardiovascular mortality, all-cause mortality, USPSTF recommendations
MeSH terms
Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fasting, Humans, Life Style, Mass Screening, United States, Glucose Intolerance, Disease Progression, Risk Assessment, Early Diagnosis, Asymptomatic Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. https://app.cochat.ai/papers/10.7326/m14-2221
The paper
Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R. (2015). Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. https://doi.org/10.7326/m14-2221

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.